Pasar al contenido principal

ESTUDIO DE LA COMUNICACION IR-GLUT1 ASTROCITICO EN LA ENFERMEDAD DE ALZHEIMER

PID2021-128737NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE NAVARRA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Astrocytic PI3Kα controls synaptic plasticity and cognitive function via serine metabolism

  • Fernández-Rodrigo, Alba
  • García-Vilela, Celia
  • Eraso-Pichot, Abel
  • Maroto, Irene B.
  • Moreno, María D. G.
  • López-Merino, Esperanza
  • Gutiérrez-Eisman, Silvia
  • Sánchez-Castillo, Carla|||/items/03d56d2b-f46a-497a-a442-751626b245e1
  • Boers-Escuder, Cristina
  • Merino-Casamayor, Eneko
  • Graupera, Mariona
  • Quintana, Albert
  • Cuartero, María I.
  • Solas, Maite
  • Marsicano, Giovanni
  • Esteban, José A.
Astrocytes modulate neuronal activity by gliotransmission and through metabolic regulation, yet the relationship between these functions remains poorly understood. Here we show that phosphatidylinositol 3-kinase (PI3K) signaling in astrocytes controls synaptic plasticity and memory by regulating cellular metabolism. Deletion of the p110α isoform of PI3K in hippocampal astrocytes impairs NMDA receptor activation during the induction of hippocampal long-term potentiation (LTP). This defect is rescued by either d-serine (co-agonist of synaptic NMDA receptors) or its precursor l-serine, indicating that PI3K regulates synaptic plasticity through serine availability. Indeed, deletion of p110α rewires astrocyte metabolism, reducing glycolytic flux while enhancing mitochondrial respiration. This, in turn, would limit l-serine biosynthesis through the phosphorylated pathway. Consistently, mice lacking astrocytic p110α display memory deficits that are rescued by in vivo l-serine administration. These findings identify astrocytic PI3K p110α as a key link between cellular metabolism, synaptic plasticity and cognition.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

  • Valdecantos, M. P.
  • Ruiz, Laura
  • Folgueira, Cintia
  • Rada, Patricia
  • Gómez-Santos, Beatriz
  • Solas, Maite
  • Hitos, Ana B.
  • Field, Joss
  • Francisco, Vera
  • Escalona-Garrido, Carmen
  • Zagmutt, Sebastián
  • Calderón‐Domínguez, María
  • Mera, Paula
  • García Martínez, Irma
  • Maymó-Masip, Elsa
  • Grajales, Diana
  • Alén, Rosa
  • Mora, Alfonso
  • Sáinz, Neira
  • Vides-Urrestarazu, Irene
  • Vilarrasa, Núria
  • Arbones-Mainar, José M
  • Zaragoza, Carlos
  • Moreno-Aliaga, María J.
  • Aspichueta, Patricia
  • Fernández-Veledo, Sonia
  • Vendrell, Joan
  • Serra, Dolors
  • Herrero, Laura
  • Schreiber, Renate
  • Zechner, Rudolf
  • Sabio, Guadalupe
  • Hornigold, David
  • Rondinone, Cristina M.
  • Jermutus, Lutz
  • Grimsby, J.
  • Valverde, Ángela M.
Bariatric surgery is effective for the treatment and remission of obesity and type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here we show how G49, an oxyntomodulin (OXM) analog and dual glucagon/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas, and liver which is initiated by a rapid release of free fatty acids (FFAs) by white adipose tissue (WAT) in a GCGR-dependent manner. This interactome leads to elevations in adiponectin and fibroblast growth factor 21 (FGF21), causing WAT beiging, brown adipose tissue (BAT) activation, increased energy expenditure (EE) and weight loss. Elevation of OXM, under basal and postprandial conditions, and similar metabolic adaptations after G49 treatment were found in plasma from patients with obesity early after metabolic bariatric surgery. These results identify G49 as a potential pharmacological alternative sharing with bariatric surgery hormonal and metabolic pathways., This work was funded by grants RTI2018-094052-B-100 funded by MICIU/AEI/10.13039/501100011033/ and by ERDF “A way of making Europe” and PID-2021-122766OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU, P2022/BMD-7227 (Comunidad de Madrid, Spain) and CIBERDdem (ISCIII) to A.M.V. and M.P.V., grants PID2020-114953RB-C21 funded by MICIU/AEI/10.13039/501100011033 to L.H. and D.S., CB06/03/0001 (CIBERobn, ISCIII, Spain) and 2021SGR00367 (Government of Catalonia) to L.H., grants PID2019-106982RB-I00 funded by MICIU/AEI/10.13039/501100011033 and CB12/03/30002 (CIBERobn, ISCIII, Spain) to M.J.M.-A., grants AECC PROYE19047SABI, PMP21/00057 Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III, PDC2021-121147-I00 funded by MICIU/AEI/10.13039/501100011033 and the “European Union NextGeneration/PRTR” and PID2022-138525OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU to G.S., grant PID2021-122480OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU, and 2021 SGR 01409 (Generalitat de Catalunya) to S.F.V., grant PID2021-128737NB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU to M.S., grants PI20/00338, PI23/01133 (ISCIII, Spain), and 2021 SGR 00829 (Government of Catalunya) to J.V., grants PI17/01556 and PI22/01773 (ISCIII, Spain) to N.V., grants IT1476-22 funded by Basque Government, Department of Education and PID2021-124425OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU to P.A. and F7302 SFB‐Lipid‐Hydrolysis from the Austrian Science Fund FWF and 12CVD04 from the Leducq Foundation both to R.Z. C.F. was funded by EASO/Novo Nordisk New Investigator Award in Basic Sciences 2023, EFSD/Novo Nordisk Rising Star 2024 and IBSA Foundation Fellowship Endocrinology 2023. V.F. was supported by “Albert Renold Travel Fellowship” grant from EFSD., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis

  • Ardanaz, Carlos G.
  • Cruz, Aída de la
  • Minhas, Paras S.
  • Hernández-Martín, Nira
  • Pozo, Miguel Angel
  • Valdecantos, M. P.
  • Valverde, Ángela M.
  • Villa-Valverde, Palmira
  • Elizalde-Horcada, Marcos
  • Puerta, Elena
  • Ramírez, María J.
  • Ortega, Jorge E.
  • Urbiola, Ainhoa
  • Ederra, Cristina
  • Ariz, Mikel
  • Ortiz de Solórzano, Carlos
  • Santamaría, Enrique
  • Karsenty, Gerard
  • Brüning, Jens C.
  • Solas, Maite
Astrocytes are considered an essential source of blood-borne glucose or its metabolites to neurons. Nonetheless, the necessity of the main astrocyte glucose transporter, i.e., GLUT1, for brain glucose metabolism has not been defined. Unexpectedly, we found that brain glucose metabolism was paradoxically augmented in mice with astrocytic GLUT1 reduction (GLUT1ΔGFAP mice). These mice also exhibited improved peripheral glucose metabolism especially in obesity, rendering them metabolically healthier. Mechanistically, we observed that GLUT1-deficient astrocytes exhibited increased insulin receptor–dependent ATP release, and that both astrocyte insulin signaling and brain purinergic signaling are essential for improved brain function and systemic glucose metabolism. Collectively, we demonstrate that astrocytic GLUT1 is central to the regulation of brain energetics, yet its depletion triggers a reprogramming of brain metabolism sufficient to sustain energy requirements, peripheral glucose homeostasis, and cognitive function., This work was financially supported by grants SAF2017-87619-P and PID2021-128737NB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe,” and NARSAD Young Investigator grant from the Brain & Behavior Research Foundation (grant number 28177). This work was also supported by a grant from CIBERDEM (ISCIII, Spain) to M.P.V. and Á.M.V. C.G.A. is supported by an FPU (Formación de Profesorado Universitario) fellowship from the Spanish Ministry of Universities (FPU18/01458)., Peer reviewed
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis

  • Ardanaz, Carlos G.
  • Cruz, Aida de la
  • Minhas, Paras S.
  • Hernández-Martín, Nira
  • Pozo, Miguel Ángel
  • Valdecantos, M. Pilar
  • Martínez Valverde, Ángela
  • Villa-Valverde, Palmira
  • Elizalde-Horcada, Marcos
  • Puerta, Elena
  • Ramírez, María J.
  • Ortega, Jorge E.
  • Urbiola, Ainhoa
  • Ederra, Cristina
  • Ariz Galilea, Mikel
  • Ortiz de Solórzano, Carlos
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Karsenty, Gerard
  • Brüning, Jens C.
  • Solas, Maite
Astrocytes are considered an essential source of blood-borne glucose or its metabolites to neurons. Nonetheless, the necessity of the main astrocyte glucose transporter, i.e., GLUT1, for brain glucose metabolism has not been defined. Unexpectedly, we found that brain glucose metabolism was paradoxically augmented in mice with astrocytic GLUT1 reduction (GLUT1ΔGFAP mice). These mice also exhibited improved peripheral glucose metabolism especially in obesity, rendering them metabolically healthier. Mechanistically, we observed that GLUT1-deficient astrocytes exhibited increased insulin receptor–dependent ATP release, and that both astrocyte insulin signaling and brain purinergic signaling are essential for improved brain function and systemic glucose metabolism. Collectively, we demonstrate that astrocytic GLUT1 is central to the regulation of brain energetics, yet its depletion triggers a reprogramming of brain metabolism sufficient to sustain energy requirements, peripheral glucose homeostasis, and cognitive function., This work was financially supported by grants SAF2017-87619-P and PID2021-128737NB-I00 funded by MCIN/AEI/10.13039/501100011033 and by 'ERDF A way of making Europe', and NARSAD Young Investigator grant from the Brain & Behavior Research Foundation (grant number 28177). This work was also supported by a grant from CIBERDEM (ISCIII, Spain) to M.P.V. and Á.M.V. C.G.A. is supported by an FPU (Formación de Profesorado Universitario) fellowship from the Spanish Ministry of Universities (FPU18/01458).